Cynthia Aranow, ACR 2021: Subcutaneous Belimumab and Rituximab Sequential Therapy in Systemic Lupus Erythematosus
It was a pleasure to speak with Professor Cynthia Aranow (Feinstein Institutes for Medical Research, Northwell Health, New York, NY, USA) around the BLISS-BELIEVE study, investigating sequential belimumab and rituximab therapy in SLE (NCT03312907).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘Efficacy and Safety of Subcutaneous Belimumab (BEL) and Rituximab (RTX) Sequential Therapy in Patients with Systemic Lupus Erythematosus: The Phase 3, Randomized, Placebo-Controlled BLISS-BELIEVE Study.’ (ABSTRACT NUMBER: L13) was presented at the ACR Convergence, 5-9 November 2021.
- What are the unmet needs in the treatment of patients with systemic lupus erythematosus (SLE)? (0:25)
- What is the rationale for sequential belimumab and rituximab therapy in SLE? (1:31)
- What were the aims, design and inclusion criteria of the BLISS-BELIEVE study? (3:31)
- What were the efficacy, safety and tolerability findings of the study? (5:29)
- Following these findings, what future studies are planned? (6:43)
Disclosures: Cynthia Aranow discloses consulting for GlaxoSmithKline, Kezar Life Sciences, Bristol Myers Squibb and AstraZeneca.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Victoria Jones.
Filmed in coverage of the virtual ACR Convergence 2021.
Share this Video
Related Videos In Systemic Lupus Erythematosus
Kevin Winthrop, ACR 2022: Anifrolumab for systemic lupus erythematosus – safety findings from the 3-year TULIP extension study
TULIP-1 (NCT02446912) and TULIP-2 (NCT02446899) were phase 3, randomized, double-blind, placebo-controlled trials that investigated the efficacy and safety of anifrolumab, a fully human IgG1 κ monoclonal antibody, in the treatment of systemic lupus erythematosus. In this touchIMMUNOLOGY interview, we caught up with Prof. Kevin Winthrop (Oregon Health & Science University, Portland, OR, USA) to learn more about […]
Victoria P. Werth, ACR 2022: Findings from the phase 2 LILAC study of BIIB059 in cutaneous lupus erythematosus
Part B of the phase 2 LILAC study (NCT02847598) investigated BIIB059, a humanized monoclonal antibody against BDCA2, for the treatment of cutaneous lupus erythematosus (CLE). In this touchIMMUNOLOGY interview, we were delighted to speak with Prof. Victoria P. Werth (University of Pennsylvania, Philadelphia, PA, USA) around the unmet needs in the treatment of CLE, the […]
Jorge Sanchez-Guerrero, ACR 2022: Belimumab for mucocutaneous manifestations of systemic lupus erythematosus – findings from a pooled post hoc analysis
Mucocutaneous manifestations affect over 80% of patients with systemic lupus erythematosus (SLE) and can significantly impact on patient quality of life. touchIMMUNOLOGY were delighted to speak with Prof. Jorge Sanchez-Guerrero (University of Toronto, Toronto, ON, Canada) around his post hoc analysis investigating the effects of belimumab on the mucocutaneous manifestations of SLE. This information is […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!